Tiny Robots Could End Weeks of Heart Infection IVs

Engineers at Johns Hopkins have built wireless magnetic millirobots — roughly as wide as a pencil tip and about as long as a grain of rice — that travel through the bloodstream to deliver antibiotics directly onto infected heart tissue while the heart keeps beating. The system, described in research published in October 2026 in the journal Advanced Materials Technologies, is aimed at endocarditis, a heart infection that strikes about 50,000 people in the United States each year, the university reported.

Today, a heart infection like that usually means four to six weeks of intravenous antibiotics, a course that often fails because the drug dilutes in the bloodstream before it reaches the heart in force, the researchers said. The infection forms sticky growths on heart valves and tissue that antibiotics struggle to penetrate, so doctors face two grim fallbacks: higher doses that can be toxic, or open-heart surgery. Current cardiology guidelines still recommend up to six weeks of antibiotic therapy for most left-sided cases of the heart infection, and the standard is not exactly working well. A recent French study of 333 patients found treatment failing in 17.1% of cases overall, with IV-only patients failing roughly twice as often as those switched early to oral drugs, as reported by Medscape.

How a needle module waits on a beating heart

The robots work as a pair. One unit, the needle module, latches gently onto the heart wall at the infection site and stays there as a docking station. The second unit, the drug module, carries its antibiotic payload through the bloodstream to the dock, locks on magnetically, and releases the medicine slowly, exactly where the heart infection has taken hold. Because the needle module stays behind, the drug module can be swapped out for fresh doses without re-navigating the heart, giving doctors a built-in refill mechanism, the team said.

Both bots are steered wirelessly by an external electromagnetic coil system that works like an MRI machine, so neither carries batteries or motors. "Magnetic guidance is exciting because you don't have to power the robot itself," said senior author Axel Krieger. The pair has so far been tested on phantom heart models and real pig heart tissue, traveling autonomously even against simulated blood flow, according to the researchers.

The result could compress heart infection treatment dramatically. The team estimates the whole procedure might take anywhere from minutes to about an hour, with repeat rounds possible in a single day — a stark contrast with the standard multi-week drip. "It's really the frontier of surgical robotics," Krieger said of the broader approach.

A track record in surgical autonomy

Krieger's lab has earned credibility in this space before — and it is not alone, with surgical robots posting a record shipment year across the industry, as GenZ NewZ reported. In 2022, its Smart Tissue Autonomous Robot — STAR — performed laparoscopic surgery on a pig's soft tissue without human guidance, reconnecting two ends of intestine with better results than human surgeons across four animal trials, as described in the journal Science Robotics. A follow-up system later performed gallbladder removals on cadavers guided by AI models, with movements the researchers described as smoother than an expert human hand, according to Fierce Biotech. The millirobot project applies the same instinct for autonomy — navigation without a surgeon's hand on the controls — at a far smaller scale, this time aimed squarely at the heart infection problem.

The road ahead is still long. The millirobots have not yet been tested in a living animal; the next step is trials in realistic phantom hearts with contracting muscle and true beating motion, and human trials of a heart infection treatment would come only after live-animal safety studies clear. The work was supported by a National Science Foundation robotics grant.

For heart infection patients, the promise is concrete: a pinprick instead of an opened chest, and hours instead of weeks tethered to an IV pole. Beyond heart infections, the team sees the same steerable approach delivering targeted drugs to tumors and other hard-to-reach disease sites — a future where the medicine goes to the disease, not the other way around. First author Anuruddha Bhattacharjee, now an assistant professor at the University of Alabama at Birmingham, summed up the vision: inject the robot with its little pill into a vein, and it travels straight to the site where the drugs are really needed.